The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.
TARRYTOWN, N.Y.--(BUSINESS WIRE)--The IMA Group (IMA) today announced the acquisition of Chicago Research Center (CRC), an independent, Chicago-based clinical research site. The addition further ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial ...
The Oncology Institute expands its partnership with Helios Clinical Research to enhance patient access to clinical trials and improve oncology care. The Oncology Institute, Inc. (TOI) announced an ...
Dr. Robert Schwartz, Chief Medical Officer of Autonomix Medical, announced successful results from the initial trial phase of their proof-of-concept study, POC 1, which demonstrated significant pain ...
IMA Clinical Research expands national footprint with leading CNS and sleep research site The IMA Group (IMA) today announced the acquisition of Chicago Research Center (CRC), an independent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback